#grfs

New Season, GRFS Returns

Continuing our pre-season series of blogs and previews, we caught up with Grass Roots Football Show host, Sam Garrett on his thoughts on the local football scene, including Pompey Academy and Pompey Ladies. (more…)

New Post has been published on http://www.stockmarketsdaily.com/is-there-value-for-investors-grifols-s-a-nasdaqgrfs/16169/

Is there Value for Investors: Grifols S.A. (NASDAQ:GRFS)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Grifols, S.A. (NASDAQ:GRFS) a company in the Healthcare industry which traders have been highly interested in of late, to assess if it provides value for investors considering buying or selling it. Currently Grifols, S.A. is trading at $32.10 after moving up 3.65% in the previous day of trading. [Trend Analysis]

GRFS is trading with a trailing 12 month P/E multiple of 40.63 and an estimated forward P/E multiple of 14.02. The stock has an estimated 5 year annual growth of 14.99% and a PEG multiple of 2.71.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Grifols, S.A. is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of GRFS. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of GRFS being 2.71, we consider Grifols, S.A. to likely be overpriced.

This analysis means that value buyers who do not currently hold Grifols, S.A. (NASDAQ:GRFS) should not consider buying and investors currently holding the stock should consider selling.

New Post has been published on http://www.stockmarketsdaily.com/fundamental-analysis-grifols-s-a-nasdaqgrfs/15744/

Fundamental Analysis: Grifols S.A. (NASDAQ:GRFS)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Grifols, S.A. (NASDAQ:GRFS) [Trend Analysis] a company in the Healthcare industry currently at the attention of investors, to assess if it provides value for investors considering buying or selling it. Currently Grifols, S.A. is trading at $31.97 after moving down -0.62% in the previous day of trading.

GRFS is trading with a trailing 12 month P/E multiple of 41.52 and an estimated forward P/E multiple of 14.27. The stock has an estimated 5 year annual growth of 14.99% and a PEG multiple of 2.77.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Grifols, S.A. is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of GRFS. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of GRFS being 2.77, we consider Grifols, S.A. to likely be overpriced.

This analysis means that value buyers who do not currently hold Grifols, S.A. (NASDAQ:GRFS) should not consider buying and investors currently holding the stock should consider selling.